J Behcet Uz Child Hosp. 2013; 3(1): 33-37 | DOI: 10.5222/buchd.2013.033
Topical 0.05% cyclosporin A therapy in children with severe vernal keratoconjunctivitis Emine Şeker Ün, Şenay Aşık Nacaroğlu Tepecik Teaching And Research Hospital OBJECTIVE: To investigate the effectiveness of 0.05% cyclosporin A therapy in children with severe vernal keratoconjunctivitis METHODS: Between 2010 and 2012, 19 patients with a diagnosis of vernal keratoconjunctivitis were involved into the study. The diagnosis of vernal conjunctivitis was made according to the presence of typical clinical symptoms. The symptoms and signs determined in the patients were seperately scored. For each patient, topical cyclosporine treatment was initiated, and at the 3. and 6. months of the therapy, scoring of the symptoms and signs were performed again. RESULTS: The mean age of the participating patients (12 male, 7 female) was 10.1 ± 1.7. The scores of the symptoms showed significant improvement during the controls performed at the 3. and 6. months of the treatment. Despite the scores were not significantly improved at the 3. month of the treatment; significant improvements were observed during the controls at the 6.month of the treatment. No adverse effects which causes the end of treatment were observed. CONCLUSION: Topical 0.05% cyclosporine A treatment was proved to cause significant improvement in clinical signs and symptoms in severe patients with active vernal keratoconjunctivitis. The need for steroids was found to be significantly reduced in these cases. The drug is well tolerated locally. Keywords: vernal keratoconjunctivitis, cyclosporine A, prognosis Ciddi vernal keratokonjonktivitli çocuklarda topikal %0,05 siklosporin A tedavisi Emine Şeker Ün, Şenay Aşık Nacaroğlu Tepecik Eğitim Araştırma Hastanesi AMAÇ: Ciddi vernal keratokonjonktivitli çocuklarda %0,05 siklosporin A tedavisinin etkinliğini araştırmak YÖNTEMLER: : 2010-2012 tarihleri arasında kliniğimizde vernal keratokonjonktivit tanısı alan 19 hasta çalışmaya dahil edildi. Vernal keratokonjonktivitli olguların tanısı tipik klinik bulgulann varlığına göre konuldu. Tüm hastaların semptom ve bulguları skorlandı. Hastalara topical siklosporin tedavisi başlandı. 3. ve 6. ayda tekrar semptom ve bulgu skorlamaları yapıldı. BULGULAR: Hastaların yaş ortalaması 10.1±1.7 idi. Olguların 12’si erkek, 7’si kadındı. Hastaların semptom skorlarında hem 3. ay hemde 6. ay kontrollerinde belirgin iyileşme saptandı. Hastaların bulgu skorlarında 3. ay kontrollerinde iyileşme belirgin değil iken, 6. ay kontrollerinde belirgin iyileşme ortaya çıkmıştır. Hastaların hiçbirinde tedaviyi kesmeyi gerektiren yan etki ortaya çıkmamıştır. SONUÇ: Ciddi aktif vernal keratokonjonktivitli hastalarda topikal %0.05 siklosporin A tedavisi klinik semptom ve bulgularda anlamlı düzelme sağlamıştır. Olgularda steroid gereksinimi belirgin olarak azalmıştır. İlaç lokal olarak iyi tolere edilmektedir. Anahtar Kelimeler: vernal keratokonjonktivit, siklosporin A, prognoz Emine Şeker Ün, Şenay Aşık Nacaroğlu. Topical 0.05% cyclosporin A therapy in children with severe vernal keratoconjunctivitis. J Behcet Uz Child Hosp. 2013; 3(1): 33-37 Corresponding Author: Emine Şeker Ün, Türkiye	TOOLS Full Text PDF Print Download citation RIS EndNote BibTex Medlars Procite Reference Manager Share with email Share Send email to author Similar articles PubMed Google Scholar  (37 accesses)  (2158 downloaded)

Journal of Behcet Uz Children's Hospital is indexed by the Web of Science-Emerging Sources Citation Index, EBSCO Academic Search Database, Google Scholar, Microsoft Academic Search, Ulakbim TR Dizin, Türk Medline, the Turkish Citation Index, J-Gate and Cabi.